ZVRA Zevra Therapeutics Inc.
Company Analysis
Latest News
🟢 Zevra Therapeutics is trading 5% up amid broader biotech strength
Zevra Therapeutics is trading 5.14% higher at $10.02, with the move occurring alongside sector and market strength rather than a confirmed company-specific...
🟢 Zevra Therapeutics is trading 7% up in pre-market as catalyst remains unclear
Zevra Therapeutics is trading 7.03% up in pre-market at $10.50 on October 26, with the catalyst unclear. - The supplied price context compares the pre-market...
🔴 Zevra Therapeutics is trading 5% down alongside biotech-sector weakness
Zevra Therapeutics is trading at $9.79, down 5.23%, amid biotech weakness; available evidence does not establish a direct cause for the decline. - No clear...
🟢 Zevra Therapeutics is trading 8.1% up in after-hours trading with no verified catalyst identified
Zevra Therapeutics is trading at $10.74, up 8.09% after hours, and the reason for the move remains unclear. - No company-specific announcement dated October...
🟢 Zevra Therapeutics is trading 5% up in after-hours trading with no confirmed news trigger
Zevra Therapeutics is trading at $10.75, up 5.10% from the October 14 regular-session close of $10.23, with no confirmed news trigger. - No fresh company...
🔴 Zevra Therapeutics is trading 5% down; no catalyst identified in available coverage
Zevra Therapeutics is trading at $10.71, down 5.39%, with no fresh company-specific announcement or catalyst identified in available coverage to explain the...
🔴 Zevra Therapeutics is trading 7.2% down in pre-market
Zevra Therapeutics is trading 7.22% lower at $10.28 in pre-market; no clear company-specific announcement for October 8, 2026, was identified. - The latest...
🟢 Zevra Therapeutics is trading 6.5% up in pre-market with no clear catalyst identified
Zevra Therapeutics is trading at $11.80, up 6.50% pre-market, with no clear catalyst identified. - No company-specific announcement dated October 8 was...
🟢 Zevra Therapeutics is trading 5% up today
Zevra Therapeutics is trading 5.22% higher at $11.29, with no specific catalyst identified. - No company-specific announcement dated October 7, 2026, was...
🟢 Zevra Therapeutics is trading 5% up today amid S&P 500 and Nasdaq gains
Zevra Therapeutics is trading at $10.53, up 5.41%, alongside a stronger market; no definitive cause has been established. - The S&P 500 was up 0.70%, and the...
🔴 Zevra Therapeutics is trading 5.3% down with no clear company-specific catalyst
Zevra Therapeutics is trading 5.3% down at $10.39 on October 1, 2026, with no clear company-specific catalyst identified in the latest company releases. - The...
🟢 Zevra Therapeutics is trading 5.1% up in pre-market with no verified company-specific catalyst identified
Zevra Therapeutics is trading 5.1% up at $12.44, with no verified company-specific catalyst identified for September 18, 2026. - Recent coverage centers on...
🔴 Zevra Therapeutics is trading 5% down in pre-market amid weaker Nasdaq futures and broader risk-off conditions
Zevra Therapeutics is trading 5.16% down now at $11.39, based on the provided pre-market price context, as weaker Nasdaq futures and broader risk-off...
🔴 Zevra Therapeutics is trading 5% down today as Brent crude tops $100 amid U.S.-Iran escalation
Zevra Therapeutics is trading 5% down at $12.04 as risk-off conditions weigh on equities. - The S&P 500, Nasdaq Composite, and Dow Jones are all lower. -...
Woodline Partners Takes 8.1% Zevra Stake, Following 53% Revenue Growth
Woodline Partners LP disclosed an 8.1% stake in Zevra Therapeutics in an August 14, 2026, regulatory filing. The investment firm holds 4,785,771 shares of...
Zevra Therapeutics Price Targets Climb, Following Massive Q2 Earnings Beat
HC Wainwright raised its 2027 earnings per share (EPS) estimate for Zevra Therapeutics from $0.46 to $0.55 on August 10. The firm maintained its Buy rating and...